Alexa
  • Directory of Taiwan

Heart Failure Drugs Market Size 2022 Industry Share, Global Trend, In-Depth Players Analysis, Revenue, COVID-19 Impact and Recovery, Supply, Development Growth, Upcoming Demand

The “Global Heart Failure Drugs Market” will grow at a CAGR of 9.1% during the forecast period. Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sampl...

Osteoporosis Drugs Market 2022: Top Players, Emerging Demand, Business Profit Analysis, Sales Revenue and Expansion Strategies by 2025

The global osteoporosis drugs market will grow at a CAGR of 4.3% during the forecast period. Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-r...

Chen says WHO trials for Taiwan's Medigen key to recognition

TAIPEI (Taiwan News) — The head of the Central Epidemic Command Center (CECC) on Wednesday (Oct. 27) said that the inclusion of Taiwan's domestic COVID-19 vaccine developed by Medigen Vaccin...

Philippines included in WHO trials of Taiwan's Medigen vaccine

TAIPEI (Taiwan News) — The World Health Organization (WHO) is including Taiwan's domestic COVID-19 vaccine developed by Medigen Vaccine Biologics Corp. (高端疫苗, MVC) in Phase III trials to be ...

WHO includes Taiwan's Medigen vaccine in Phase III trials

TAIPEI (Taiwan News) — The World Health Organization (WHO) is including Taiwan's domestic COVID-19 vaccine developed by Medigen Vaccine Biologics Corp. (高端疫苗, MVC) in its Phase III trials an...

Taiwan's second domestic COVID vaccine's midterm performance in phase II trials inferior to local competitor: experts

TAIPEI (Taiwan News) — Taiwan’s United Biomedical, Inc. (UBI) on Sunday (June 27) released the midterm study report for the phase II clinical trials of its COVID-19 vaccine UB-612, claimin...

Ocumension Therapeutics: Annual Results Announcement For The Year Ended December 31, 2020

HONG KONG SAR - Media OutReach - 22 March 2021 - The Board of Directors of the Company is pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 20...

Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States

HONG KONG SAR - Media OutReach - 22 February 2021 - This announcement is made by Ocumension Therapeutics (the "Company", together with its subsidiaries, the "Group") on a voluntary basis to keep the s...

ITM Announces Appointment of Philip E. Harris as New Chief Medical Officer

GARCHING, Germany--(BUSINESS WIRE)--Jun 6, 2018--ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced the appointment of Philip E. Harris, BSc MB BCh ...

Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018

SUMMIT, N.J.--(BUSINESS WIRE)--Jun 3, 2018--Celgene Corporation (NASDAQ:CELG) today announced additional results from RELEVANCE, a phase III, randomized, open-label, international clinical study condu...

Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma

SUMMIT, N.J.--(BUSINESS WIRE)--Jun 1, 2018--Celgene Corporation (NASDAQ:CELG) today announced results from the OPTIMISMM study, a phase III, randomized, open-label, international clinical study of the...

Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease  

INGELHEIM, Germany--(BUSINESS WIRE)--May 23, 2018--For media excluding US/Canada and UK This press release features multimedia. View the full release here: https://www.businesswire.c...